The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017

References

• Ministry of Health. Cancer patient survival 1994–2011. Wellington: Ministry of Health; 2020.
   Google Scholar
• Organisation for Economic Co-operation and Development. OECD Health Statistics, Paris, France. 2020.
   Google Scholar
• Ministry of Health, Wellington, New Zealand. Cancer: historical summary. 2020. p. 1948–2017.
   Google Scholar
• Bioinformatics and Drug Design Group. Therapeutic target database, Zhejiang University.  Hangzhou, China. 2020.
   Google Scholar
• New Zealand Medicines and Medical Devices Safety Authority. Product/application search, Wellington, New Zealand. 2020.
   Google Scholar
• Romer PM. Endogenous technological change. J Political Econ. 1990;98(5):S71–102.
   Web of Science ®Google Scholar
• Grossman GM, Helpman E. Quality ladders in the theory of growth. Rev Econ Stud. 1991;58(193):43–61. January
   Google Scholar
• Broda C WDW, Weinstein DE. Variety growth and world welfare. Am Econ Rev. 2004;94(2):139–144.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. WISQARS years of potential life lost (YPLL) report, Atlanta, Georgia. 2020.
   Google Scholar
• Statistical Office of the European Union. Eurostat. 2020, Luxembourg City, Luxembourg.
   Google Scholar
• Organization for Economic Co-operation and Development. OECD health statistics 2020 database, Paris, France. 2020.
   Google Scholar
• World Health Organization. Global health estimates: life expectancy and leading causes of death and disability, Geneva, Switzerland. 2020.
   Google Scholar
• World Health Organization. WHO methods and data sources for global burden of disease estimates 2000-2016. Geneva: Department of Information, Evidence and Research; 2018. June
   Google Scholar
• Food and Drug Administration. Drugs approved for different types of cancer, Silver Spring, Maryland. 2020.
   Google Scholar
• Lichtenberg FR. The effect of pharmaceutical innovation on longevity: patient level evidence from the 1996–2002 medical expenditure panel survey and linked mortality public-use files. Forum Health Econ Policy. 2013;16(1):1–33. January
   PubMedGoogle Scholar
• Lichtenberg FR. Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000–2009. Health Policy Technol. 2014;3(1):36–58. March
   Web of Science ®Google Scholar
• Dorsey ER, et al. Financial anatomy of biomedical research, 2003-2008. J Am Med Assoc. 2010;303(2):137–143.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Enhancing drug discovery and development, Bethesda, Maryland. 2020.
   Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009. Econ Hum Biol. 2014;13:107–127. [ March]
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. Has medical innovation reduced cancer mortality? CESifo Economic Studies. 2014;60(1): 135–177.
   Web of Science ®Google Scholar
• National Cancer Institute. Long-term trial results show no mortality benefit from annual prostate cancer screening, Bethesda, Maryland. February 17. 2012.
   Google Scholar
• Barber JM, Sheehy KP. Uptake of new medicines in New Zealand: evidence of a waiting list. NZ Med J. 2015;128(1412): 17 April, Wellington, New Zealand
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling, Silver Spring, Maryland. 2020.
   Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997–2010. J Hum Capital. 2014;8(4):432–480. Winter
   Web of Science ®Google Scholar
• World Health Organization. Cause of death query online, Geneva, Switzerland. 2020.
   Google Scholar
• New Zealand Ministry of Health. Mortality 2017 data tables, Wellington, New Zealand. 2020.
   Google Scholar
• Ministry of Health. Discharges from publicly funded hospitals – 1 July 2004 to 30 June 2005. Wellington: Ministry of Health; 2020.
   Google Scholar
• Ministry of Health. Publicly funded hospital discharges - 1 July 2012 to 30 June 2013. Wellington: Ministry of Health; 2020.
   Google Scholar
• Ministry of Health. Publicly funded hospital discharges – 1 July 2016 to 30 June 2017. Wellington: Ministry of Health; 2020.
   Google Scholar
• Wang YX, Zhang S, Li FC, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031–D1041.
   PubMed Web of Science ®Google Scholar
• Ministry of Health. The price of cancer: the public price of registered cancer in New Zealand. Wellington: Ministry of Health, September; 2011.
   Google Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016 September;94(12):925–930.
   PubMed Web of Science ®Google Scholar
• Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Allocation. 2003;1(1). 8, Dec 19 10.1186/1478-7547-1-8
   Google Scholar
• National Cancer Institute. Crunching numbers: what cancer screening statistics really tell us, Bethesda, Maryland. 2020.
   Google Scholar
• Solow RM. Investment and technological progress. In: Arrow K, Karlin S, Suppes P, editors. Mathematical methods in social sciences 1959. Stanford University Press; 1960. p. 89–104.
   Google Scholar
• Nobelprize.org. The prize in economics 1987 - press release,  Stockholm, Sweden. 2020.
   Google Scholar
• Association of Public Health Epidemiologists in Ontario. Calculating potential years of life lost (PYLL), Hamilton, Ontario. 2020.
   Google Scholar
• Lichtenberg FR. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Econ Innovation New Technol. 2009;18(5):407–428. July
   Google Scholar